CG Oncology, Inc. Common stock – NASDAQ:CGON
CG Oncology, Inc. Common stock stock price today
$25.56
-4.48
-14.91%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
CG Oncology, Inc. Common stock stock price monthly change
-15.16%
month
CG Oncology, Inc. Common stock stock price quarterly change
-15.16%
quarter
CG Oncology, Inc. Common stock key metrics
Market Cap | 2.14B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCG Oncology, Inc. Common stock stock price history
CG Oncology, Inc. Common stock stock forecast
CG Oncology, Inc. Common stock financial statements
Average Price Target
$62.33
Potential upside: 143.87%
Analysts Price target
Financials & Ratios estimates
| 2023 | 204K | -48.60M | -23826.96% |
|---|
| 2024-05-09 | -0.35 | -0.36 |
|---|
| 2023 | 199301000 | 14.51M | 7.28% |
|---|
| 2022 | -29.80M | -55.35M | 119.69M |
|---|---|---|---|
| 2023 | -45.67M | -121.19M | 86.99M |
CG Oncology, Inc. Common stock alternative data
| Mar 2024 | 61 |
|---|---|
| Apr 2024 | 61 |
| May 2024 | 61 |
| Jun 2024 | 61 |
| Jul 2024 | 61 |
| Dec 2024 | 61 |
CG Oncology, Inc. Common stock other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 400000 | 0 |
| Dec 2024 | 0 | 702000 |
CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene
CG Oncology Bringing Undervalued Innovation To Bladder Cancer
CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value
U.S. IPO Weekly Recap: Biotech CG Oncology Pops 96% In A 7 IPO Week
CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality
-
What's the price of CG Oncology, Inc. Common stock stock today?
One share of CG Oncology, Inc. Common stock stock can currently be purchased for approximately $25.56.
-
When is CG Oncology, Inc. Common stock's next earnings date?
Unfortunately, CG Oncology, Inc. Common stock's (CGON) next earnings date is currently unknown.
-
Does CG Oncology, Inc. Common stock pay dividends?
No, CG Oncology, Inc. Common stock does not pay dividends.
-
How much money does CG Oncology, Inc. Common stock make?
CG Oncology, Inc. Common stock has a market capitalization of 2.14B. CG Oncology, Inc. Common stock made a loss 48.61M US dollars in net income (profit) last year or -$0.36 on an earnings per share basis.
-
What is CG Oncology, Inc. Common stock's stock symbol?
CG Oncology, Inc. Common stock is traded on the NASDAQ under the ticker symbol "CGON".
-
What is CG Oncology, Inc. Common stock's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of CG Oncology, Inc. Common stock?
Shares of CG Oncology, Inc. Common stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does CG Oncology, Inc. Common stock have?
As Dec 2024, CG Oncology, Inc. Common stock employs 61 workers.
-
What is CG Oncology, Inc. Common stock stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for CG Oncology, Inc. Common stock in the last 12 months, the avarage price target is $62.33. The average price target represents a 143.87% change from the last price of $25.56.
CG Oncology, Inc. Common stock company profile:
Exchange:
NASDAQ
Full time employees:
61
Industry:
Biotechnology
Sector:
Healthcare
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
,
CIK: 0001991792
ISIN: US1569441009
:
